Brolucizumab

Indication

Treating diabetic macular oedema - NICE TA820

Red

Brand:

Nice TA:

820

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:

Eye

1.1 Brolucizumab is recommended as an option for treating visual impairment due to diabetic macular oedema in adults, only if:

the eye has a central retinal thickness of 400 micrometres or more at the start of treatment
the company provides brolucizumab according to the commercial arrangement.

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

BwD	BP	CSR	EL	FW	GP	MB	WL
Red	Red	Red	Red	Red	Red	Red	Red

What do the colours mean?

Last Updated: 14 - Sep - 2022